Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 11/20 | 0.83 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.65 |
| ▸ | KIT | P10721 | 4/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | KDR | P35968 | 4/20 | 0.61 |
| ▸ | IGF1R | P08069 | 1/20 | 0.60 |
| ▸ | CSF1R | P07333 | 2/20 | 0.58 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.58 |
| ▸ | FLT4 | P35916 | 1/20 | 0.58 |
| ▸ | FLT3 | P36888 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | AXL | P30530 | 1/20 | 0.55 |
| ▸ | MERTK | Q12866 | 1/20 | 0.55 |
| ▸ | RET | P07949 | 1/20 | 0.54 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30314058 | 1.00 | MET (0.83) | METPDGFRAKITMEN1KMT2A | |
| SCHEMBL19711697 | 0.91 | MET (0.81) | METPDGFRAKITMEN1KMT2A | |
| SCHEMBL371934 | 0.91 | MET (1.00) | METPDGFRAKITMEN1KMT2A | |
| SCHEMBL371684 | 0.91 | MET (0.72) | METPDGFRAKITKDRIGF1R | |
| SCHEMBL372754 | 0.89 | MET (0.70) | METPDGFRAKITKDRIGF1R | |
| SCHEMBL371727 | 0.89 | MET (0.70) | METPDGFRAKITKDRIGF1R | |
| SCHEMBL4993698 | 0.87 | MET (0.68) | METPDGFRAKITKDRIGF1R | |
| SCHEMBL409601 | 0.87 | MET (0.68) | METPDGFRAKITKDRIGF1R | |
| SCHEMBL21301531 | 0.87 | MET (0.85) | METPDGFRAKITKDRCSF1R | |
| SCHEMBL31324673 | 0.87 | MET (0.85) | METPDGFRAKITKDRCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. | 2021-08-19 | — | — | US | claimed |
| US-20200331860-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2020-10-22 | — | — | US | claimed |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2017-12-14 | — | — | US | claimed |
| US-20160185725-A1 | c-Met Modulators and Method of Use | EXELIXIS, INC. | 2016-06-30 | — | — | US | claimed |
| US-20150376133-A1 | C-Met Modulators and Methods of Use | EXELIXIS, INC. | 2015-12-31 | — | — | US | claimed |
| US-20120022065-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2012-01-26 | — | — | US | claimed |
| WO-2009017838-A2 | COMBINATIONS OF JAK-2 INHIBITORS AND OTHER AGENTS | EXELIXIS, INC. (US) | 2009-02-05 | — | — | WO | claimed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | claimed |
| CN-116763787-A | New application of quinoline compound | 安徽中科拓苒药物科学研究有限公司 | 2023-09-19 | — | — | CN | disclosed |
| WO-2023168740-A1 | NOVEL USE OF QUINOLINE COMPOUND | 安徽中科拓苒药物科学研究有限公司 | 2023-09-14 | — | — | WO | disclosed |
| CN-111303024-B | Quinoline-structured pan-KIT kinase inhibitor and application thereof | 安徽中科拓苒药物科学研究有限公司 | 2023-03-28 | — | — | CN | disclosed |
| EP-3329918-B1 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2022-05-25 | — | — | EP | disclosed |
| US-20220064117-A1 | PAN-KIT KINASE INHIBITOR HAVING QUINOLINE STRUCTURE AND APPLICATION THEREOF | Tarapeutics Science Inc. (CN) | 2022-03-03 | — | — | US | disclosed |
| US-11124482-B2 | C-met modulators and methods of use | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331860-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | MET 3/4885PDGFRA 63/4885KIT 5/4885 |
| US-20070054928-A1 | c-Met modulators and methods of use | FLT4, FLT1, MET | MET 3/4885PDGFRA 63/4885KIT 5/4885 |
| US-20120022065-A1 | C-Met Modulators and Method of Use | FLT4, MET, FLT1 | MET 2/4885PDGFRA 182/4885KIT 4/4885 |
| US-20150376133-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | MET 3/4885PDGFRA 63/4885KIT 5/4885 |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | MET 3/4885PDGFRA 63/4885KIT 5/4885 |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | FLT4, FLT1, MET | MET 3/4885PDGFRA 63/4885KIT 5/4885 |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | MET 2/4885PDGFRA 182/4885KIT 4/4885 |
| US-20160185725-A1 | c-Met Modulators and Method of Use | FLT4, MET, FLT1 | MET 2/4885PDGFRA 182/4885KIT 4/4885 |
| US-11124482-B2 | C-met modulators and methods of use | FLT4, FLT1, MET | MET 3/4885PDGFRA 63/4885KIT 5/4885 |
| US-20220064117-A1 | PAN-KIT KINASE INHIBITOR HAVING QUINOLINE STRUCTURE AND APPLICATION THEREOF | KIT, MAP3K7, ABL1 | MET 1150/4885PDGFRA 747/4885KIT 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.